BioMarin Gyrates as Bears and Bulls Spar Over Gene Therapy Data

(Bloomberg) -- BioMarin Pharmaceutical Inc. shares fluctuated after the market open as three-year data for the company’s Hemophillia A gene therapy failed to meet the most bullish investor expectat...

Bloomberg Quint

Add BloombergQuint App to Home screen.